AI brief of an SEC Form 8-K · H.B. Fuller (FUL)

H.B. Fuller to acquire Advanced Medical Solutions for 285 pence per share in cash

Mixed Impact 5 of 5 m&a Written later

H.B. Fuller and the board of Advanced Medical Solutions Group plc (AMS) agreed terms on a recommended cash offer, to be implemented through a UK court-sanctioned scheme of arrangement. The company has arranged bridge credit agreements of up to $2,086,713,188 (secured) and $917,000,000 (unsecured) to fund the deal and refinance debt, and expects completion by the end of calendar 2026, which would add new borrowings for shareholders to weigh against the strategic growth case.

Key points

  • AMS shareholders will receive 285 pence in cash per AMS share; the press release cites a total enterprise value of £715 million.
  • Secured Bridge Credit Agreement of up to $2,086,713,188 and Unsecured Bridge Credit Agreement of up to $917,000,000, both with Goldman Sachs Bank USA; loans would mature 364 days after closing.
  • Completion is expected by the end of calendar 2026, subject to AMS shareholder approval, High Court sanction, regulatory approvals, and a Long-Stop Date of June 25, 2027.
  • Company expects approximately $55 million in combined run-rate revenue and cost synergies by 2031.

The filing

CompanyH.B. Fuller (FUL)
Form8-K, current report
Filed with the SECJun 26, 2026, 4:31 PM ET
Accession number0001437749-26-021844

Items reported: 1.01 Material Definitive Agreement2.03 New Direct Financial Obligation7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:49 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on June 26, 2026.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.